Skip to main content
  • SGLT2 Inhibitor Poised to Reach Beyond Diabetes Into HF

    Cardiologists see broader use as a mandate, perhaps even in HFpEF

    Spurred on by the big win with dapagliflozin (Farxiga) in DAPA-HF last week, the sodium glucose cotransporter-2 (SGLT2) inhibitors appear poised for broader use in heart failure with reduced ejection fraction (HFrEF) and are even eyeing cases with preserved EF.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details